Sepsis
Conditions
Interventions
Control group:CRRT and corresponding clinical treatment were given to ensure that the filters used for CRRT treatment in the experimental group and the control grou
Experimental Group:HA380 hemoperfusion therapy
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.>=18 years old; 2. Weight >=30 kilograms; 3. Meet the Sepsis 3.0 diagnostic criteria for sepsis; 4. Patients with AKI at stage 2 or above as classified by KDIGO; 5. The occurrence time of sepsis is no more than 72 hours; 6. Interleukin-6 (IL-6) > 500 pg/ml;
Exclusion criteria
Exclusion criteria: 1.Patients with highly contagious infectious diseases, such as those with open tuberculosis; 2.Pregnant women, parturient women and lactating women; 3.Unable to perform blood purification and/or hemoperfusion treatment for various reasons; 4.Expected to die within 48 hours of admission to the ICU; 5.Patients who have received cardiopulmonary resuscitation (CPR) within the past week, organ transplant patients, and patients who have been using immunosuppressants for a long time; 6.Patients who have not signed the informed consent form; 7.Patients who are currently participating in or have participated in other clinical trials within the past month; 8.The researcher believes that participating in the trial poses a significant risk to the health or safety of the subjects, may affect the evaluation of the therapeutic effect, or there are other circumstances that are not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory factors;Serum creatinine, Acute Physiology and Chronic Health Evaluation (APACHE), and Sequential Organ Failure Assessment (SOFA) score changes; | — |
Secondary
| Measure | Time frame |
|---|---|
| The utilization rate and dosage of vasoactive drugs within 72 hours after the start of hemoperfusion treatment;The renal function status at 7, 14, and 28 days after the start of hemoperfusion treatment and the time to discontinue hemodialysis;The transfer-out rate from the ICU and survival status on the 7th, 14th, and 28th days after the start of hemoperfusion treatment;The time to wean from the ventilator after the start of hemoperfusion treatment;The length of hospital stay and ICU stay after the start of hemoperfusion therapy;The improvement rate of hemodynamic indicators including cardiac index (CI) and systemic vascular resistance index (SVRI); | — |
Countries
China
Contacts
Public ContactLi Yingchuan
Shanghai Tenth People's Hospital
Outcome results
None listed